en · de · es · fr · pt
aod-9604-notes.peptides6579.com › Blog › Identity And Molecular Context — Evidence Review

Identity And Molecular Context — Evidence Review

By Editorial Desk · published 2026-06-05 · last reviewed 2026-07-12 · Blog

Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-07-12. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from a fragment of human growth hormone
Sequence basishGH residues 176-191Commonly described as a 16-amino-acid fragment
AppearanceWhite to off-white powderTypical for lyophilized research peptides
SolubilitySoluble in water or aqueous bufferExact solubility depends on pH and purity
Common synonymsAOD9604; hGH 176-191Spelling and punctuation vary across sources

Identity and Research Context

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Related pages on this site

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Reference notes

Marketers use well-researched techniques to try to control purchasing behavior. The layout of a supermarket is considered by some to consist of a few rules of thumb and three layout principles. The high-draw products are placed in separate areas of the store to keep drawing the consumer through the store. High impulse and high margin products are placed in the most predominant areas to grab attention. Power products are placed on both sides of the aisle to create increased product awareness, and end caps are used to receive a high exposure of a certain product whether on special, promotion or in a campaign, or a new line. The first principle of the layout is circulation. Circulation is created by arranging product so the supermarket can control the traffic flow of the consumer. Along with this path, there will be high-draw, high-impulse items that will influence the consumer to make purchases which they did not originally intend. Service areas such as restrooms are placed in a location which draws the consumer past certain products to create extra buys. Necessity items such as bread and milk are found at the rear of the store to increase the start of circulation. Cashiers' desks are placed in a position to promote circulation. In most supermarkets, the entrance will be on the right-hand side because some research suggests that consumers who travel in a counter-clockwise direction spend more. However, other researchers have argued that consumers moving in a clockwise direction can form better mental maps of the store leading to higher sales in turn.

== Preservation of microbiology cultures == Bacteria and fungi can be kept short-term (months to about a year, depending) refrigerated, however, cell division and metabolism is not completely arrested and thus is not an optimal option for long-term storage (years) or to preserve cultures genetically or phenotypically, as cell divisions can lead to mutations or sub-culturing can cause phenotypic changes. A preferred option, species-dependent, is cryopreservation. Nematode worms are the only multicellular eukaryotes that have been shown to survive cryopreservation.

== Non-traditional use == In the late 20th century, the practice of ayahuasca drinking began spreading to Europe, North America and elsewhere. The first ayahuasca churches, affiliated with the Brazilian Santo Daime, were established in the Netherlands. A legal case was filed against two of the Church's leaders, Hans Bogers (one of the original founders of the Dutch Santo Daime community) and Geraldine Fijneman (the head of the Amsterdam Santo Daime community). Bogers and Fijneman were charged with distributing a controlled substance (DMT); however, the prosecution was unable to prove that the use of ayahuasca by members of the Santo Daime constituted a sufficient threat to public health and order such that it warranted denying their rights to religious freedom under ECHR Article 9. The 2001 verdict of the Amsterdam district court is an important precedent. Since then groups that are not affiliated to the Santo Daime have used ayahuasca, and a number of different "styles" have been developed, including non-religious approaches. In Peru, retreat centers such as Blue Morpho, founded by Hamilton Souther, in Iquitos began offering ayahuasca ceremonies to foreign visitors around 2004. International media coverage brought wider attention to the practice and coincided with the growth of ayahuasca tourism.

Sources: en.wikipedia.org

Notes from published material

== Clinical significance == A mutation in the tyrosinase gene resulting in impaired tyrosinase production leads to type I oculocutaneous albinism, a hereditary disorder that affects one in every 20,000 people. Tyrosinase activity is very important. If uncontrolled during the synthesis of melanin, it results in increased melanin synthesis. Decreasing tyrosinase activity has been targeted for the improvement or prevention of conditions related to the hyperpigmentation of the skin, such as melasma and age spots. Several polyphenols, including flavonoids or stilbenoid, substrate analogues, free radical scavengers, and copper chelators, have been known to inhibit tyrosinase. Henceforth, the medical and cosmetic industries are focusing research on tyrosinase inhibitors to treat skin disorders.

Lenin was immediately committed to avoid antagonising the peasantry by making efforts to coax them away from the Socialist Revolutionaries, allowing a peasant takeover of nobles' estates while no immediate nationalisations were enacted on peasants' property. The Decree on Land (8 November 1917) fulfilled Lenin's promised redistribution of Russia's arable land to the peasants, who reclaimed their farmlands from the aristocrats, ensuring the peasants' loyalty to the Bolshevik party. To overcome the civil war's economic interruptions, the policy of War Communism (1918–1921), a regulated market, state-controlled means of distribution and nationalisation of large-scale farms, was adopted to requisite and distribute grain in order to feed industrial workers in the cities whilst the Red Army was fighting the White Army's attempted restoration of the Romanov dynasty as absolute monarchs of Russia. Moreover, the politically unpopular forced grain-requisitions discouraged peasants from farming resulted in reduced harvests and food shortages that provoked labour strikes and food riots. In the event, the Russian peoples created an economy of barter and black market to counter the Bolshevik government's voiding of the monetary economy. In 1921, the New Economic Policy restored some private enterprise to animate the Russian economy.

=== Membrane and self-assembling peptide studies === Membrane proteins and self-assembly properties of certain proteins can be studied under this technique, due to being a label-free calorimeter. Membrane proteins are known to have difficulties with selection of proper solubilization and purification protocols. As ITC is a non-destructive calorimetric tool, it can be used as a detector to locate the fraction of protein with desired binding sites, by binding a known binding ligand to the protein. This feature also applies in studies of self-assembling proteins, especially in use of measuring thermodynamics of their structural transformation.

In August 2022, after months of suspension due to the Russian invasion of Ukraine, Starbucks sold all its stores in Russia to the Russian rapper Timati. The stores were rebranded as "Stars Coffee", and are very similar to the former stores. Starbucks said it had no comment on the new owner. On October 1, 2022, Howard Schultz stepped down as CEO, with Laxman Narasimhan becoming Starbucks's next CEO. On March 23, 2023, Narasimhan told employees that he would work a half-day behind a store counter each month, and he trained as a barista to immerse himself in the brand and stay close to customers. In June 2023, Starbucks was ordered to pay $25 million in punitive damages and $600,000 compensatory damages to a former regional manager. The court found that Starbucks fired her in 2018 because she was white. In December 2023, the operator of all of the Starbucks locations in Brazil, SouthRock Capital, declared itself bankrupt. SouthRock would continue to operate Starbucks locations normally while closing a few underperforming ones and would restructure through the bankruptcy procedure. SouthRock Capital later declared Chapter 15 bankruptcy in June 2024. On August 13, 2024, Starbucks announced it was replacing then CEO Laxman Narasimhan with Brian Niccol. Niccol had served as the CEO of Chipotle since 2018. In January 2025, Starbucks ended its 'open-door policy', and requires customers to make a purchase in order to use restrooms and the seating area. In February 2025, Starbucks cut 30% of its menu in an effort to simplify its processes and reduce costs.

Sources: en.wikipedia.org

Further detail

In addition to drinks and food, many stores carry Starbucks' official merchandise, such as mugs, tumblers, scoops, and coffee presses. There are also several select "Starbucks Evenings" locations that offer beer, wine, and appetizers. Starbucks-brand coffee, ice cream, and bottled cold coffee drinks are sold at grocery stores in the United States and other countries. In 2010, the company began its Starbucks Reserve program for single-origin coffees and high-end coffee shops. It planned to open 1,000 Reserve coffee shops by the end of 2017. However, since succeeding Schultz, Johnson has scaled back the Reserve coffee shops to only six to ten shops. Further development on Reserve coffee shops would be dependent on the success of the few already in existence. Currently, Starbucks operates six coffee roasteries with tasting rooms and 43 coffee bars as part of the program. As of February 2023, Starbucks had 36,171 locations open across 83 countries, with 61% of the locations operating in the U.S. and China, and the rest operating elsewhere. In February 2024, the chain unveiled a new store design aimed at improving accessibility. The first location to use this design is the Washington, D.C. Union Market store. The company plans for all future company-owned stores to adopt a similar design.

=== Lutzner cells === Lutzner cells are bigger than normal lymphocytes and contain extensive folding in their membrane. They are described at being cerebriform in shape, and can be diploid or tetraploid. It also contains a large nucleus with a minimum cytoplasm. Lutzner cells are more predominant in Mycosis Fungoides, but are also found in Sézary Syndrome.

=== Active site === Eflornithine's suicide inhibition of ODC physically blocks the natural substrate ornithine from accessing the active site of the enzyme (Figure 3). There are two distinct active sites formed by the homodimerization of ornithine decarboxylase. The size of the opening to the active site is approximately 13.6 Å. When these openings to the active site are blocked, there are no other ways through which ornithine can enter the active site. During the intermediate stage of eflornithine with PLP, its position near Cys-360 allows an interaction to occur. As the phosphate of PLP is stabilized by Arg 277 and a Gly-rich loop (235–237), the difluoromethyl group of eflornithine is able to interact and remain fixated to both Cys-360 and PLP prior to transimination. As shown in the figure, the pyrroline ring interferes with ornithine's entry (Figure 4). Eflornithine will remain permanently bound in this position to Cys-360. As ODC has two active sites, two eflornithine molecules are required to completely inhibit ODC from ornithine decarboxylation.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

What is the exact length of AOD-9604?

It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.

Does AOD-9604 occur naturally?

It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Network